-
IDWeek Commentary | Dr. Hongmei Xu: CMV PCR Agreement between Blood and Dried Blood Spots in Infants with Congenital Cytomegalovirus Infection
Infants can be infected with congenital cytomegalovirus (CMV) through vertical mother-to-child transmission, and CMV infection screening is required for some newborns with specific indications. Polymerase chain reaction (PCR) is a commonly used clinical method for qualitative or quantitative diagnosis of CMV, and it can test specimens such as urine, plasma, and dried blood spots, each…
-
Dr. Lungen Lu: Intermittent Fasting vs. Standard Caloric Restriction – A Better Approach to Improving NAFLD Fibrosis and Metabolism
Dietary adjustments currently stand as the primary treatment for Non-Alcoholic Fatty Liver Disease (NAFLD). At the 58th European Association for the Study of the Liver (EASL) Annual Meeting (EASL 2023), Deepankshi Aggarwal from India presented their team’s latest findings in an oral presentation. They discussed how time-restricted intermittent fasting may be superior to standard caloric…
-
Dr.Jinshui Pan’s Team: Revealing the Heavy Tumor Burden Caused by Metabolic Risk Factors Worldwide (1990-2019)
Non-alcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver disease, often coexisting with various metabolic risk factors, which are significantly associated with the risk of various tumors. Dr.Jinshui Pan and ProfessoDr. Shang Weng from the Liver Disease Center of Fujian Medical University Affiliated First Hospital, along with Dr. Meizhu Hong from Mengchao…
-
Dr.Wai-Kay Seto’s team Multiple Studies on Hepatic Diseases Management with New Hepatitis B Drugs Fatty Liver Monitoring and Liver Cancer Risk Factors
The 58th Annual Meeting of the European Association for the Study of the Liver (EASL2023) and the EASL Congress 2023 have come to a close. During this conference, Dr. Wai-Kay Seto and his research team from The University of Hong Kong Shenzhen Hospital/ The University of Hong Kong presented several studies. Hepatology Digest had the…
-
Dr. Wenshi Wang’s Team: Three Latest Research Findings on Hepatitis D and Hepatitis E Included in Conference Exchange
Hepatitis D (HDV) is a viral hepatitis caused by hepatitis D virus (HDV) infection, often occurring as a co-infection or superinfection with hepatitis B virus (HBV). Approximately 90% of chronic hepatitis B patients who become co-infected with HDV develop chronic hepatitis, increasing the risk of adverse outcomes such as liver failure, cirrhosis, and liver cancer.…
-
ESMO Expert Commentary | Roxadustat Non-inferior to Standard Treatment, Poised to Transform Clinical Practice in Chemotherapy-Induced Anemia
Platinum-based, taxane, anthracycline, and other chemotherapy drugs are commonly used in the treatment of various cancers such as breast and lung cancer. However, these chemotherapy agents, known marrow suppressors, can lead to chemotherapy-induced anemia (CIA), resulting in a decline in functional capacity and diminished quality of life for patients. This year’s ESMO conference revealed the…
-
Dr. Chao Wu: Current State and Prospects of Clinical Cure for Hepatitis B
Clinical cure of hepatitis B has been a hot topic in the field of viral hepatitis, and the 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the 2023 EASL Congress unveiled numerous advancements in new drug research. Dr. Chao Wu and his team from the Department of…
-
Dr. Yong-an Ye’s Team: Predicting Virological Recurrence in Chronic Hepatitis B with Machine Learning After Entecavir Discontinuation
Currently, most chronic hepatitis B (CHB) patients cannot achieve a cure. While guidelines suggest that some CHB patients can discontinue nucleos(t)ide analogs (NAs) after consolidation therapy, virological recurrence remains common. Early virological recurrence typically predicts disease flare-up; however, there are limited biomarkers for assessing the risk of virological recurrence after treatment cessation. Dr. Yong-an Ye…
Connecting Medical Expertise through Media